2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, APL, Translational Research, MDS, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

5177 Gemtuzumab ozogamicin based salvage therapy for relapsed/refractory acute myeloid leukemia after venetoclax failure: A multicenter real-world study

Daniel Yehuda, MD, Khaled Sandouka, MD2, Miri Neaman, MD3, Yakir Moshe, MD, PhD4, Avraham Frisch5, Tzvika Porges, MD6, Pia Raanani, MD7, Alon Rozental, MD8, Boaz Nachmias, MD PhD9, Ofir Wolaj, MD10
1 Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel
2 Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
3 Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
4 Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
5 Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion., Haifa, Israel
6 Soroka Medical Center, Beer-sheva, Israel
7 Felsenstein Medical Research Center, Rabin Medical Center, Petah Tikva, Israel, Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel
8 Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel
9 Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
10 Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel

Background: Venetoclax (ven)-containing lower-intensity approaches are considered standard-of-care for patients (pts.) with acute myeloid leukemia (AML), that are ineligible for intensive induction therapy. Disease resistance after exposure to ven-containing regimens (ven-failure) is a high-risk clinical scenario that is associated with very poor outcomes and limited salvage options. Gemtuzumab Ozogamicin (GO) is an anti-CD33 antibody-drug conjugate that has shown clinical activity in the relapsed/refractory (RR) AML setting as monotherapy, or in combination with chemotherapy. The efficacy and safety of GO-based salvage approaches was not systematically assessed after ven-failure.

Methods: A retrospective multi-center study of consecutive adult pts. treated with GO-based salvage approaches for RR AML after previous exposure to ven-based low intensity regimens. The decision on GO-containing salvage intensity and combination was at the discretion of the treating physician. Primary study outcome was overall response rate (ORR; CR+CRi+MLFS+PR). Secondary outcomes included overall survival (OS), complete remission (CR), transition to allogeneic stem-cell transplantation (alloSCT), and safety.

Results: 21 pts. were included in the analysis. Median age was 76 years (range 61-80), with 67% male and 28% with ECOG >=2. De novo AML was documented in 57% of pts., and secondary AML occurred in 43%, including therapy related AML in 3 pts. According to the ELN 2022 risk stratification 43% (9 pts.) had adverse risk AML, and 14% (3 pts.) had favorable risk disease. ELN 2024 re-stratified two pts. with an IDH mutation to the favorable group.

All patients received lower-intensity frontline induction (86% containing hypomethylating agents). After frontline induction, 90% of patients (n=19), achieved a composite CR with median CR duration of 9.6 months (mos., range 2.3-35.4). 26% of cohort had an early relapse (<6 months). The median lines of therapy prior to GO-based salvage were 1 (range 1-4). Five patients (24%) received an additional low-intensity salvage treatment line before GO based salvage. Three pts. (14%) were exposed to a molecular targeted agent prior to GO based salvage: gilteritinib (n=2) or ivosidenib (n=1). At initial diagnosis, the median percent of blasts expressing CD33 was 88.0% (range, 0-100).

GO based salvage was given as monotherapy in 38% of patients (n=8), or combined with low, intermediate or high dose cytarabine in 62% (n=13) of pts. GO was capped at 4.5 mg in 67% of patients and given at 3 mg/m2 (capped at 5 mg) in 33%, with an average of 2.5 doses per patient (median 3, range 1-3).

Early death within 30-days of salvage was high, at 38% (n=8). In the remaining 13 pts. ORR was noted in 46% (n=6 of 13 evaluable pts.) with CR in 3 pts., MLFS in 2 pts. and one PR. 5 of 6 responding patients were treated for late relapse (>6 mos.), and all responding patients received GO in combination with cytarabine rather than GO monotherapy. One patient was successfully bridged to alloSCT after GO based salvage.

With a median follow-up period of 3.3 mos., the median OS from GO salvage initiation was 2.6 mos., with 6- and 12-mos. OS of 27% and 21%. Only one patient of cohort is alive at last follow up.
OS from GO salvage was not affected by timing of relapse but was significantly associated with ELN risk: median OS for ELN 2022 adverse, intermediate and favorable risk pts. was 1, 3.7 and 7 mos., respectively (log-rank p=0.015), and for ELN 2024 median OS was 0.8, 4.4 and 7 mos. (log-rank p=0.004).

The main adverse events were grade 3-4 neutropenia that occurred in 95% of patients and febrile neutropenia in 71%. No case of sinusoidal obstructive syndrome (SOS) was noted, including in the one patient bridged to alloSCT. Elevated liver function tests were noted in 85% of evaluated pts. (all but one, grade ≤2). Severe infection and sepsis were the leading cause of death, accounting for 60% of deaths.

Conclusion: This real-world multicenter cohort confirms the poor overall outcome of older patients with AML relapsing after ven-containing low-intensity induction. GO-containing salvage approaches achieved modest response rates, restricted to pts. receiving GO in combination with cytarabine. Early mortality was significant, mostly due to infectious complications. These findings highlight the need for effective and tolerable salvage strategies in older pts., especially in the era of ven-based, lower intensity frontline induction.

Daniel Yehuda, MD: No relevant conflicts of interest to declare.